Assessing of the Therapeutic Efficacy of These 2 Treatment Regimens in the Management of <i>Helicobacter pylori</i> Infection at Kinshasa — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Assessing of the Therapeutic Efficacy of These 2 Treatment Regimens in the Management of <i>Helicobacter pylori</i> Infection at Kinshasa
Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
,
Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
,
Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
,
Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
,
Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
,
Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
,
Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
,
Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
,
Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
,
Department of Medical Biologie, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
,
Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
,
Foundation Aurore, Kinshasa, DR Congo
,
University Catholique of Bukavu, Bukavu, DR Congo
,
Lomo University of Research, Kinshasa, DR Congo
1 Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
2 Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
3 Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
4 Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
5 Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
6 Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
7 Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
8 Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
9 Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
10 Department of Medical Biologie, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
11 Department of Internal medicine, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, DR Congo
12 Foundation Aurore, Kinshasa, DR Congo
13 University Catholique of Bukavu, Bukavu, DR Congo
14 Lomo University of Research, Kinshasa, DR Congo
Introduction : Helicobacter pylori (Hp) infection is a worldwide public health problem. Unfortunately, its management poses a problem because of resistance to antibiotics. However, there are codified treatment protocols covering sequential and concomitant quadritherapy with regard to first-line probabilistic treatment. The objective of this study was to assess the therapeutic efficacy of these 2 treatment regimens in the management of Hp infection at Kinshasa. Methods : This was a mixed study, with documentary, descriptive and interventional approaches, carried out between September 1, 2018 and April 30, 2020. Results : Sixty-four patients were collected, including 36 men against 28 women with a sex ratio of 1H:1F; the mean age was 54 ± 16.5 years. There was an over-representation of senior patients (n = 29); an intermediate number of adult patients (n = 22) and a lower number of young patients (n = 13). 34 and 30 were respectively treated according to the concomitant and sequential regimens. Concomitant quadruple therapy offered an eradication rate of 91.2% compared to 56.7% for sequential quadruple therapy; concomitant treatment, advancing age and absence of risky behavior more quickly predicted the occurrence of eradication success. Conclusion : The present study showed superiority of concomitant quadruple therapy over sequential quadruple therapy in first-line treatment. Alcohol with active smoking had a negative influence, while concomitant quadruple therapy, advancement in age had a positive influence on the success of the eradication of Hp infection.
Hooi, J.K.Y., Lai, W.Y., Ng, W.K., Suen, M.M.Y., Underwood, F.E., Tanyingoh, D., et al. (2017) Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology, 153, 420-429. https://doi.org/10.1053/j.gastro.2017.04.022
Vincent, P., Gottrand, F. and Leclerc, H. (1996) Epidemiology of Helicobacter pylori: Disparities in the Distribution of Infection. Gastroentérologie Clinique et Biologique, 20, S27-S33.
Perez-Perez, G.I., Rothenbacher, D. and Brenner, H. (2004) Epidemiology of Heli- cobacter pylori Infection. Helicobacter, 9, 1-6. https://doi.org/10.1111/j.1083-4389.2004.00248.x
Parkinson, A.J., Gold, B.D., Bulkow, L., Wainwright, R.B., Swaminathan, B., Khanna, B., et al. (2000) High Prevalence of Helicobacter pylori in the Alaska Native Population and Association with Low Serum Ferritin Levels in Young Adults. Clinical and Diagnostic Laboratory Immunology, 7, 885-888. https://doi.org/10.1128/CDLI.7.6.885-888.2000
Zabala Torrres, B., Lucero, Y., Lagomarcino, A.J., Orellana-Manzano, A., George, S., Torres, J.P., et al. (2017) Review: Prevalence and Dynamics of Helicobacter pylori infection during Childhood. Helicobacter, 22, Article No. e12399. https://doi.org/10.1111/hel.12399
Lim, S.H., Kwon, J.W., Kim, N., Kim, G.H., Kang, J.M., Park, M.J., et al. (2013) Prevalence and Risk Factors of Helicobacter pylori Infection in Korea: Nationwide Multicenter Study over 13 Years. BMC Gastroenterology, 13, Article No. 104. https://doi.org/10.1186/1471-230X-13-104
Jang, K.M., Choe, B.H., Choe, J.Y., Hong, S.J., Park, H.J., Chu, M.A., et al. (2015) Changing Prevalence of Helicobacter pylori Infections in Korean Children with Recurrent Abdominal Pain. Pediatric Gastroenterology, Hepatology & Nutrition, 18, 10-16. https://doi.org/10.5223/pghn.2015.18.1.10
Sjomina, O., Pavlova, J., Niv, Y. and Leja, M. (2018) Epidemiology of Helicobacter pylori Infection. Helicobacter, 23, Article No. e12514. https://doi.org/10.1111/hel.12514
Eusebi, L.H., Zagari, R.M. and Bazzoli, F. (2014) Epidemiology of Helicobacter pylori Infection. Helicobacter, 19 , 1-5. https://doi.org/10.1111/hel.12165
Hong, W., Tang, H.-L., Dong, X.-L., Hu, S.-K., Yan, Y., Basharat, Z., et al. (2019) Prevalence of Helicobacter pylori Infection in a Third-Tier Chinese City: Relationship with Gender, Age, Birth-Year and Survey Years. Microbiota in Health and Disease, 1, Article No. e150.
Argueta, E.A. and Moss, S.F. (2019) Treatment of Helicobacter pylori. Current Opinion in Gastroenterology, 35, 544-550. https://doi.org/10.1097/MOG.0000000000000578
Matsumoto, H., Shiotani, A. and Graham, D.Y. (2019) Current and Future Treatment of Helicobacter pylori Infections. In: Kamiya, S. and Backert, S., Eds., Helicobacter pylori in Human Diseases, Vol. 1149, Springer, Cham, 211-225. https://doi.org/10.1007/5584_2019_367
Hu, Y., Zhu, Y. and Lu, N.-H. (2020) Recent Progress in Helicobacter pylori Treatment. Chinese Medical Journal, 133, 335-343. https://doi.org/10.1097/CM9.0000000000000618
Patrick, N.K. (2018) Gastroduodenal Pathologies and Antibiotic Sensitivities during Helicobacter pylori Infection in Kinshasa in 2017. Specialization Thesis.
A Q&A and Howden, C.W. (2021, July 14) Helicobacter pylori: Current Treatment Options and Challenges. The American Journal of Managed Care®, 19-20.
Li, B.Z., Threapleton, D.E., Wang, J.Y., Xu, J.M., Yuan, J.Q., Zhang, C., et al. (2015) Comparative Effectiveness and Tolerance of Treatments for Helicobacter pylori: Systematic Review and Network Meta-Analysis. BMJ, 351, Article No. h4052. https://doi.org/10.1136/bmj.h4052
Gatta, L., Vakil, N., Vaira, D. and Scarpignato, C. (2013) Global Eradication Rates for Helicobacter pylori Infection: Systematic Revieward Meta-Analysis of Sequential Therapy. BMJ, 347, Article No. f4587. https://doi.org/10.1136/bmj.f4587
Cuadrado-Lavín, A., Salcines-Caviedes, J.R., Diaz-Perez, A., Carrascosa, M.F., Och- agavía, M., Fernandez-Forcelledo, J.L., et al. (2015) First-Line Eradication Rates Comparing Two Shortened Non-Bismuth Quadruple Regimens against Helicobacter pylori: An Open-Label, Randomized, Multicentre Clinical Trial. Journal of Antimicrobial Chemotherapy, 70, 2376-2381. https://doi.org/10.1093/jac/dkv089
Mc Nicholl, A.G., Marin, A.C., Molina-Infante, J., Castro, M., Barrio, J., Ducons, J., et al. (2014) Randomised Clinical Trial Comparing Sequential and Concomitant Therapies for Helicobacter pylori Eradication in Routine Clinical Practice. Gut, 63, 244-249. https://doi.org/10.1136/gutjnl-2013-304820
Nkondi Nsenga, J., Longo-Mbenza, B., Kabongo Mpolesha, J.M., Mabwa, L., Mbungu, S. and Vangu, D. (2007) Seropositivity for Helicobacter pylori, Helicobacter pylori Gastritis, Blood Pressure Components: Reality of Cardiovascular Risk. Journal Africain d’Hépato-Gastroentérologie, 1, 87-92. https://doi.org/10.1007/s12157-007-0021-x
Malfertheiner, P., Megraud, F., O’morain, C., Gisbert, J., Kuipers, E., Axon, A., et al. (2017) Management of Helicobacter pylori Infection—The Maastricht V/Florence Consensus Report. Gut, 66, 6-30. https://doi.org/10.1136/gutjnl-2016-312288
Monteiro, L. and Mégraud, F. (1999) By What Means Should Helicobacter pylori Be Tested before and after Eradication? Clinical and Biological Gastroenterology, 23, 3C-19C.
Correa, P. (1988) A Human Model of Gastric Carcinogenesis. Cancer Research, 48, 3554-3560.
Crowe, S.E. (2019) Helicobacter pylori Infection. New England Journal of Medicine, 380, 1158-1165. https://doi.org/10.1056/NEJMcp1710945
Lamarque, D., Burucoa, C., Courillon-Mallet, A., de Korwin, J.-D., Delchier, J.-C., Heluwaert, F., et al. (2017) Recommendations for Treatment of Helicobacter pylori Infection in Adults. Hepato-Gastro & Digestive Oncology, 24, 157-170.
Ibrahim, A., Morais, S., Ferro, A., Lunet, N. and Peleteiro, B. (2017) Sex-Differences in the Prevalence of Helicobacter pylori Infection in Pediatric and Adult Populations: Systematic Review and Meta-Analysis of 244 Studies. Digestive and Liver Disease, 49, 742-749. https://doi.org/10.1016/j.dld.2017.03.019
The Eurogast Study Group (1993) Epidemiology of, and Risk Factors for, Helico- bacter pylori Infection among 3194 Asymptomatic Subjects in 17 Populations. Gut, 34, 1672-1676. https://doi.org/10.1136/gut.34.12.1672
Janulaityte-Gunther, D., Kupcinskas, L., Pavilonis, A., Valuckas, K., Andersen, L.P. and Wadstrom, T. (2009) Helicobacter pylori Antibodies and Gastric Cancer: A Gender-Related Difference. FEMS Immun Med Microbiol, 44, 191-195. https://doi.org/10.1016/j.femsim.2004.11.011
Nijevitch, A., Khamidullina, S. and Khamidullina, F. (1999) Childhood Duodenal Ulcer Associated with Helicobacter pylori and ABO Blood Groups. American Journal of Gastroenterology, 94,1424-1425. https://doi.org/10.1111/j.1572-0241.1999.01424.x
Ozaydin, N., Turkyilmaz, S.A. and Cali, S. (2013) Prevalence and Risk Factors of Helicobacter pylori in Turkey: A Nationally-Representative, Cross-Sectional, Screening with the 13C-Urea Breath Test. BMC Public Health, 13, Article No. 1215. https://doi.org/10.1186/1471-2458-13-1215
Eisdorfer, I., Shalev, V., Goren, S., Chodick, G. and Muhsen, K. (2018) Sex Differences in Urea Breath Test Results for the Diagnosis of Helicobacter pylori Infection: A Large Cross-Sectional Study. Biology of Sex Differences, 9, Article No. 1. https://doi.org/10.1186/s13293-017-0161-7
Mabeku, L.B.K., Ngamga, M.L.N. and Leundji, H. (2018) Potential Risk Factors and Prevalence of Helicobacter pylori Infection among Adult Patients with Dyspepsia Symptoms in Cameroon. BMC Infectious Diseases, 18, Article No. 278. https://doi.org/10.1007/s10620-005-2762-y
Kanbay, M., Gür, G., Arslan, H., Yilmaz, U. and Boyaciogˇ Lu, S. (2005) The Rela- tionship of ABO Blood Group, Age, Gender, Smoking, and Helicobacter pylori Infection. Digestive Diseases and Sciences, 50, 1214-1217. https://doi.org/10.1007/s10620-005-2762-y
Park, J.S., Jun, J.S., Seo, J.-H., Youn, H.-S. and Rhee, K.-H. (2021) Changing Prevalence of Helicobacter pylori Infection in Children and Adolescents. Clinical and Experimental Pediatrics, 64, 21-25. https://doi.org/10.3345/cep.2019.01543
Dimitriadi, D. (2014) Helicobacter pylori: A Sexually Transmitted Bacterium? Central European Journal of Urology, 67, 407-409. https://doi.org/10.5173/ceju.2014.04.art18
Sgambato, D., Visciola, G., Ferrante, E., Miranda, A., Romano, L., Tuccillo, C., et al. (2018) Prevalence of Helicobacter pylori Infection in Sexual Partners of H. pylori- Infected Subjects: Role of Gastroesophageal Reflux. United European Gastroenterology Journal, 6, 1470-1476. https://doi.org/10.1177/2050640618800628
Roger, A., Feldman, A., Eccersley, J.P. and Hardie, J.M. (1998) Epidemiology of Helicobacter pylori: Acquisition, Transmission, Population Prevalence and Disease- Toinfection Ratio. British Medical Bulletin, 54, 39-53. https://doi.org/10.1093/oxfordjournals.bmb.a011678
Wu, C.T., Chen, L.K. and Hwang, S.J. (2003) Seroprevalence of Helicobacter pylori in School-Aged Chinese in Tapei City and Relationship between ABO Blood Groups. World Journal of Gastroenterology, 9, 1752-1755. https://doi.org/10.3748/wjg.v9.i8.1752
Amaral, O., Fernandes, I., Veiga, N., Pereira, C., Chaves, C., Nelas, P., et al. (2017) Living Conditions and Helicobacter pylori in Adults. BioMed Research International, 2017, Article ID: 9082716. https://doi.org/10.1155/2017/9082716
Myran, L. and Zarbock, S.D. (2018) Management of Helicobacter pylori Infection. U.S. Pharmacist, 43, 27-32.
Siddalingam, R. and Chidambaram, K. (2014) Chapter 10: Helicobacter pylori. Current Therapy and Future Therapeutic Strategies. In: Roesler, M., Ed., Trends in Helicobacter pylori Infection, IntechOpen London, 200, 279-302. https://doi.org/10.5772/58338
Selecedo, J.A. and Al-Kawas, F. (1998) Treatment of Helicobacter pylori. JAMA Internal Medicine, 158, 842-851. https://doi.org/10.1001/archinte.158.8.842
Mégraud, F., O’Morain, C., Malfertheiner, P., on behalf of the Working Party of the European Helicobacter pylori Study Group (1997) Guidelines for Clinical Trials in Helicobacter 294 Trends in Helicobacter pylori Infection. Statistical Annex: Statistical Aspects of Clinical Trials in Helicobacter pylori Infection. Gut, 41, S19-S23.
Macias-Garcia, F., Baston-Rey, I., de la Iglesia-Garcia, D., Calvino-Suarez, C., Nieto-Garcia, L., Dominguez-Munoz, J.E. (2019) Bismuth-Containing Quadruple Therapy versus Concomitant Quadruple Therapy as First-Line Treatment for Helicobacter Pylori Infection in an Area of High Resistance to Clarithromycin: A Prospective, Cross-Sectional, Comparative, Opentrial. Helicobacter, 24, Article ID: e12546. https://doi.org/10.1111/hel.12546
Zullo, A., Vaira, D., Vakil, N., Hassan, C., Gatta, L., Ricci, C., et al. (2003) High Eradication Rates of Helicobacter pylori with a New Sequential Treatment. Alimentary Pharmacology & Therapeutics, 17, 719-726. https://doi.org/10.1046/j.1365-2036.2003.01461.x
Zullo, A., Fiorini, G., Scaccianoce, G., Portincasa, P., De Francesco, V., Vassallo, R., et al. (2019) Sequential Therapy for First-Line Helicobacter pylori Eradication: 10- or 14-Day Regimen? Journal of Gastrointestinal and Liver Diseases, 28, 11-14. https://doi.org/10.15403/jgld.2014.1121.281.hpy
Laving, A., Kamenwa, R., Sayed, S., Kimang’a, A.N. and Revathi, G. (2013) Effectiveness of Sequential v. Standard Triple Therapy for Treatment of Helicobacter pylori Infection in Children in Nairobi, Kenya. South African Medical Journal, 103, 921-924. https://doi.org/10.7196/SAMJ.7012
Nyssen, O.P., Mc Nicholl, A.G., Megraud, F., Savarino, V., Oderda, G., Fallone, C.A., et al. (2016) Sequential versus Standard Triple First-Line Therapy for Helicobacter pylori Eradication. Cochrane Database of Systematic Reviews, No. 6, Article No. CD009034. https://doi.org/10.1002/14651858.CD009034.pub2
Sugano, K., Tack, J., Kuipers, E.J., Graham, D.Y., El-Omar, E.M., Miura, S., et al. (2015) Kyoto Global Consensus Report on Helicobacter pylori Gastritis. Gut, 64, 1353-1367. https://doi.org/10.1136/gutjnl-2015-309252
El-Serag, H.B., Kao, J.Y., Kanwal, F., Gilger, M., LoVecchio, F., Moss, S.F., et al. (2018) Houston consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clinical Gastroenterology and Hepatology, 16, 992-1002.E6. https://doi.org/10.1016/j.cgh.2018.03.013
Liu, W.Z., Xie, Y., Lu, H., Cheng, H., Zeng, Z.R., Zhou, L.Y., et al. (2018) Fifth Chinese National Consensus Report on the Management of Helicobacter pylori infection. Helicobacter, 23, Article ID: e12475. https://doi.org/10.1111/hel.12475
Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D.L., et al. (2018) Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis. The Lancet Infectious Diseases, 18, 318-327. https://doi.org/10.1016/S1473-3099(17)30753-3
Kim, B.J., Lee, H., Lee, Y.C., Jeon, S.W., Kim, G.H., Kim, H.S., et al. (2019) Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Pylori Infection: A Nationwide Randomized Trial in Korea. Gut and Liver, 13, 531-540. https://doi.org/10.5009/gnl19136
Kapizioni, C., Koutoufaris, G., Ntouli, V., Makris, K., Milioni, K., Kourkoulis, P., et al. (2019) Optimal Duration of Concomitant Non-Bismuth Quadruple Therapy as First-Line Therapy for Helicobacter pylori: A Prospective, Open Label, Comparative Study. European Journal of Gastroenterology & Hepatology, 31, 1206-1210. https://doi.org/10.1097/MEG.0000000000001517
Kuo, C.-H., Kuo, F.-C., Hu, H.-M., Liu, C.-J., Wang, S.S.W., Chen, Y.-H., et al. (2010) Sequential and Concomitant Therapy with Four Drugs Is Equally Effective for Eradication of H pylori Infection. Clinical Gastroenterology and Hepatology, 8, 36-41.e1. https://doi.org/10.1016/j.cgh.2009.09.030
Suzuki, T., Matsuo, K., Ito, H., Sawaki, A. and Hirose, K. (2006) Smoking Increases the Treatment Failure for Helicobacter pylori Eradication. The American Journal of Medicine, 119, 217-224. https://doi.org/10.1016/j.amjmed.2005.10.003
Blanca Piazuelo, M., Mera, R. and Correa, P. (2008) Effect of Smoking on Failure of H. pylori Therapy and Gastric Histology in a High Gastric Cancer Risk Area of Colombia. Acta Gastroenterologica Latino Americana, 37, 238-245.
Takara, Y., Endo, H., Nakano, R., Kawachi, K., Hidaka, H., Matsunaga, T., et al. (2019) Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin. Digestion, 99, 172-178. https://doi.org/10.1159/000490889
Tang, Y., Tang, G., Pan, L., Zhu, H., Zhou, S. and Wei, Z. (2020) Clinical Factors Associated with Initial Helicobacter pylori Eradication Therapy: A Retrospective Study in China. Scientific Reports, 10, Article No. 15403. https://doi.org/10.1038/s41598-020-72400-0
Hassan, M., Noureddine, M., Assi, F. and Houmani, Z. (2018) Eradication Rate of Helicobacter pylori by Classic Triple Therapy in Lebanon: Is It Still Effective? International Journal of Clinical Medicine, 2, 1-5. https://doi.org/10.15761/ICM.1000129
Mamori, S., Higashida, A., Kawara, F., Ohnishi, K., Takeda, A., Senda, E., et al. (2010) Age-Dependent Eradication of Helicobacter pylori in Japanese Patients. World Journal of Gastroenterology, 16, 4176-4179. https://doi.org/10.3748/wjg.v16.i33.4176
De Francesco, V. (2019) A Novel Hybrid First-Line Therapy for H. pylori Eradication: Results of a Pilot Study. Journal of Gastrointestinal and Liver Diseases, 28, 129-130